

Solace Nutrition announces clinical and scientific updates for Encala

02 February 2026 | News

Solace Nutrition plans to expand Encala's availability internationally, with a Canadian launch anticipated in the third quarter of 2026



Solace Nutrition plans to expand Encala's availability internationally, with a Canadian launch anticipated in the third quarter of 2026

Solace Nutrition, a trusted leader in tailored clinical nutrition and medical foods, announced significant clinical, scientific, and commercial updates for Encala, its proprietary plant-based structured-lipid medical food designed to address fat malabsorption, fatty acid and choline deficiencies, poor growth in children, and unintentional weight loss in adults.

Since the February 2025 relaunch of Encala, sales supporting both adult and pediatric nutritional care have exceeded projections. Many healthcare providers recognised the Encala brand from its earlier availability through Envara Health, Inc., recalling its predictable benefits for weight gain and gastrointestinal symptom improvement in patients with malabsorption.

"In the past year, Solace Nutrition established in-house manufacturing, comprehensive patient support, insurance coverage assistance, and dedicated health care provider services with a full-time team," said Thomas Clough, CEO of Solace Nutrition. "We are now well-positioned to meet increasing patient demand across a wide range of malabsorption conditions."

Encala is currently being utilised by patients with pancreatic and intestinal diseases, short bowel syndrome, and other complex gastrointestinal conditions. Solace Nutrition plans to expand Encala availability internationally, with a Canadian launch anticipated in the third quarter of 2026 and expansion into South America by the fourth quarter. Targeted patient populations include those living with cystic fibrosis, short bowel syndrome, rare pancreatic diseases, and patients requiring ICU enteral nutrition support.